CRMD · CorMedix Inc. · Financials
$7.58
+0.20 (+2.71%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$575.23M
Shares
77.94M
Volume · Oct 20
969.45K
Avg daily vol (3M)
1.12M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$311.71M
+617%
FY2025
Net Income
$163.06M
+1009.4%
FY2025
Gross Margin
88.46%
-4.2pp
FY2025
Operating Margin
48.17%
+99.6pp
FY2025
Diluted EPS
$2.04
+780%
FY2025
Operating Cash Flow
$175.05M
+445.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $325M – $345M | $462.25M | $311.71MG | $43.47M | — | $65.41K | $190.94K | $239.23K | $283.27K | $429.8K | $329.33K | $224.11K | $210.13K | $189.27K | $2001 | $0 | — | — | — | — | — | |
| — | — | — | $1.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $4000 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $32.55M | $22.09M | $3.03M | — | $3734 | $148.94K | $204.85K | $373.23K | $396.79K | $114.96K | $366.67K | -$318.72K | -$445.8K | -$201.61K | $0 | — | — | — | — | — | |
| — | $382.64M | $275.75M | $40.28M | — | $61.67K | $42K | $34.39K | -$89.97K | $33.01K | $214.36K | -$142.57K | -$108.59K | -$256.53K | -$199.6K | $0 | — | — | — | — | — | |
| — | — | 88.46% | 92.66% | — | 94.29% | 22% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9975.21% | — | — | — | — | — | — | |
| — | $27.59M | $19.33M | $3.94M | $13.16M | $10.68M | $13.13M | $13.38M | $11.05M | $18.82M | $24.49M | $15.74M | $6.28M | $1.32M | $1.23M | $1.14M | $4.06M | $5.49M | — | — | — | |
| — | $52.18M | $38.05M | $28.74M | $18.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $85.83M | $68.22M | $29.96M | $17.69M | — | — | — | — | $8.07M | $8.65M | $8.88M | $10.26M | $7.33M | $3.49M | $1.86M | $3.15M | $3.01M | — | — | — | |
| — | $43.24M | — | — | $35.8M | $20.01M | $16.35M | $13.88M | $9.87M | $8.07M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $13.87M | $156K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $165.6M | $125.61M | $62.64M | $48.96M | $30.69M | $29.48M | $27.26M | $20.92M | $26.9M | $33.14M | $24.62M | $16.55M | $8.65M | $4.72M | $3M | $7.21M | $8.51M | — | — | — | |
| — | — | — | — | — | — | $3.01M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $217.04M | $150.14M | -$22.36M | -$48.96M | -$30.62M | -$29.44M | -$27.22M | -$21.01M | -$26.86M | -$32.92M | -$24.76M | -$16.65M | -$8.9M | -$4.92M | -$3M | -$7.21M | -$8.51M | — | — | — | |
| — | — | 48.17% | -51.43% | — | -46819.91% | -15417.51% | -11378.44% | -7416.31% | -6250.44% | -9997.39% | -11048.8% | -7925.56% | -4703.3% | -245646.93% | — | — | — | — | — | — | |
| — | — | $2.78M | $36K | $34.3K | $26.52K | $15.94K | $33.23K | $787.49K | $1873 | $5619 | $1311 | $3964 | $2087 | $1.44M | $382.94K | $0 | $3.09M | — | — | — | |
| — | — | $3.85M | $2.58M | $2.68M | — | — | $116.07K | $322.67K | $36.62K | $110.71K | $126.77K | $60.39K | $2714 | $668 | $1965 | $12.04K | $23.44K | — | — | — | |
| — | -$13.64M | -$125K | $3.03M | $2.62M | $336.65K | -$22.83K | $23.67K | -$485.98K | $34.57K | -$85.8K | — | — | — | — | — | — | — | — | — | — | |
| — | -$4357 | — | — | — | — | — | — | $268 | $0 | $13.1K | $11.03K | -$24.24K | $0 | — | — | — | — | — | — | — | |
| — | $203.4M | $150.02M | -$19.33M | -$46.34M | -$30.29M | -$29.46M | -$27.2M | -$21.49M | -$26.83M | -$33.01M | -$24.64M | -$18.19M | -$20.45M | -$9.13M | -$3.38M | -$7.17M | -$11.19M | — | — | — | |
| — | $16.23M | -$13.04M | -$1.4M | — | -$585.62K | -$1.25M | -$5.17M | -$5.06M | — | — | — | — | — | $0 | $0 | -$493.86K | -$280.92K | — | — | — | |
| — | $187.17M | $163.06M | -$17.93M | -$46.34M | -$29.7M | -$28.21M | -$22.03M | -$16.43M | -$26.83M | -$33.01M | -$24.64M | -$18.19M | -$20.45M | -$9.13M | -$3.38M | -$6.67M | -$10.91M | -$8.12M | -$9M | -$7.24M | |
| — | — | 52.31% | -41.24% | — | -45409.9% | -14774.7% | -9207.7% | -5801.29% | -6242.4% | -10023.45% | -10996.46% | -8655.37% | -10806.25% | -456426.69% | — | — | — | — | — | — | |
| — | — | — | — | — | — | $28.2M | $22M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$22.03M | -$43.54M | -$26.83M | — | -$24.64M | -$18.22M | -$20.54M | -$9.52M | -$3.38M | — | — | — | — | — | |
| — | -$78K | -$88K | -$3000 | -$46.33M | -$29.71M | -$28.23M | -$22.02M | -$16.43M | -$26.83M | -$32.99M | -$24.62M | -$18.22M | -$20.35M | -$9.14M | — | — | — | — | — | — | |
| USD/shares | — | $2.45 | $2.25 | -$0.30 | -$0.91 | -$0.74 | -$0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $2.18 | $2.04 | -$0.30 | -$0.91 | -$0.74 | -$0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 72.03K | 58.87K | 50.9M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 55.14M | 37.97M | 31.34M | 21.44M | 13.82M | 11.41M | 11.41M | — | — | — | — |
| shares | — | — | 80.31K | 58.87K | 50.9M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 55.14M | 37.97M | 31.34M | 21.44M | 13.82M | 11.41M | 11.41M | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2025-12-31 | USD 596,000 | 10-K filed 2026-03-05 |
| Current operating lease liabilities | 2025-12-31 | USD 853,000 | 10-K filed 2026-03-05 |
| Noncurrent convertible debt | 2025-12-31 | USD 144,626 | 10-K filed 2026-03-05 |
| Noncurrent finance lease liabilities | 2025-12-31 | USD 586,000 | 10-K filed 2026-03-05 |
| Noncurrent operating lease liabilities | 2025-12-31 | USD 2,253,000 | 10-K filed 2026-03-05 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.14×
EV/EBIT
—
Peer median 12.21×
P/E (TTM)
—
Peer median 10.76×
Peer medians compare against the 310 similar-size Biotechnology companies (of 559 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Europe | $190,936 | $237,025 | $274,443 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product | $304,344,000 | — |
| DefenCath | $258,813,000 | $43,472,000 |
| Melinta Portfolio | $45,531,000 | — |
| Contract Revenue | $7,365,000 | — |
Key facts
CIK
1410098
CUSIP
21900C308
13F (30d)
11 filings
11 filers
Visit website
Investor relations